Etanercept Survival in Elderly Population

Completed

• Conditions: Psoriasis

• Registration Number: NCT02503059
• Lead Sponsor: Fundación Pública Andaluza Progreso y Salud

Brief Summary

Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified.

All variables were collected through retrospective review of medical records of patients dermatology unit are made.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-11
• Primary Completion: 2015-01
• Study Completion: 2015-02
• Status Verified: 2015-07
• Study First Submitted: 2015-07-08
• Study First Submitted QC: 2015-07-16
• Last Update Submitted: 2015-07-16
• Study First Posted: 2015-07-20
• Last Update Posted: 2015-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Patients with moderate / severe psoriasis (with / without psoriatic arthritis,PAs) defined by: PASI(Psoriasis Area and Severity Index)> 10 and / or BSA(Body Surface Area)> 10% and / or DLQI(Dermatology Life Quality Index)> 10
• PASI> 10 and / or BSA(Body Surface Area)> 10% and / or DLQI(Dermatology Life Quality Index)> 10
• Over 60 years of age at the start of treatment
• Receiving etanercept at any time
• Available history in the Dermatology

Exclusion Criteria

• Patients with insufficient clinical data in the medical record

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ineffectiveness of treatment in localized lesions in patients with etanercept treatment	24 weeks(duration of treatment with etanercept)	Despite having achieved a good response PASI no improvement in critical injuries
Secondary ineffectiveness in patients with etanercept treatment	24 weeks (duration of treatment with etanercept)	Number of participants with Poor adherence to treatment with etanercept",
primary ineffectiveness in patients with etanercept treatment	24 weeks	Number of participants not achieve PASI 75 response at 24 weeks

Secondary Outcome Measures

Name	Time	Method
number of participants with Poor adherence to treatment with etanercept	24 weeks
number of participants with Conditions requiring hospitalization and / or surgery	24 weeks
Number of participants with adverse events during treatment with etanercept	24 weeks
Number of participants with disease remission	24 weeks

Trial Locations

Locations (5)

Hospital Clinic; 🇪🇸 Barcelona, Spain

H.U. Reina Sofía; 🇪🇸 Córdoba, Spain

Hospital la Paz; 🇪🇸 Madrid, Spain

Hospital de Andújar; 🇪🇸 Jaén, Spain

H.U. Virgen de la Victoria; 🇪🇸 Málaga, Spain